Last reviewed · How we verify
FOSAPREPITANT DIMEGLUMINE
At a glance
| Generic name | FOSAPREPITANT DIMEGLUMINE |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 2008 |
Approved indications
Common side effects
- fatigue
- diarrhea
- neutropenia
- asthenia
- anemia
- peripheral neuropathy
- leukopenia
- dyspepsia
- urinary tract infection
- pain in extremity
Key clinical trials
- To Evaluate the Efficacy and Safety of QLM2010 for Prevention of Chemotherapy-induced Nausea and Vomiting After Highly Emetogenic Chemotherapy. (PHASE3)
- Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy (PHASE3)
- Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-045) (PHASE4)
- Clinical Study of HR20013 for Injection in Patients With Malignant Solid Tumors (PHASE3)
- Clinical on the Safety and Efficacy of Fosaprepitant Dimeglumine for Injection in the Prevention of CINV. (NA)
- Rolapitant Hydrochloride in Preventing Nausea/Vomiting in Patients With Sarcoma Receiving Chemotherapy (PHASE2)
- Fosaprepitant Dimeglumine in Preventing Nausea and Vomiting in Patients With Gastrointestinal Cancer Receiving Combination Chemotherapy (NA)
- Study of the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children (MK-0517-029) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |